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Abstract 
The oncogenic human papilloma viruses (HPVs) are associated with precancerous cervical 
lesions and development of cervical cancer. The DNA methylation signatures of host genome in 
normal, precancerous and cervical cancer tissue may indicate tissue-specific perturbation in 
carcinogenesis. The aim of this study was to identify new candidate genes that are differentially 
methylated in squamous cell carcinoma compared to the DNA samples from cervical intraepithelial 
neoplasia grade 3 (CIN3) and normal cervical scrapes. The Illumina Infinium Human Methylation 450 
K BeadChip method identifies genome-wide DNA methylation changes in CpG islands, CpG shores 
and shelves. Our findings showed an extensive differential methylation signature in cervical cancer 
compared to the CIN3 or normal cervical tissues. The identified candidate biomarker genes for 
cervical cancer represent several types of mechanisms in the cellular machinery that are 
epigenetically deregulated by hypermethylation, such as membrane receptors, intracellular signaling 
and gene transcription. The results also confirm the extensive hypomethylation in cancer cells of 
genes in the immune system. These insights into the functional role of DNA methylome alterations in 
cervical cancer could be clinically applicable in diagnostics and prognostics, and may guide the 
development of new epigenetic therapies. 
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Introduction 
Cervical cancer is the third most frequent cancer among women world-wide.1 The causative 
agent is a persistent infection with one of fifteen oncogenic human papilloma viruses (HPVs) that 
leads to cervical precancerous lesions which may progress to cancer.2 There are more than 100 
identified HPV genotypes, 40 of them are considered to infect the genital tract and the types 16, 18 
and 45 are found to be the most common in cervical cancer.3  
The majority of the viral load is cleared by the cell-mediated immunity, but if it is not 
cleared the persistent infection affects the host cell apoptosis and cell cycle control, cell adhesion 
and DNA repair mechanisms.4 It may also activate inflammatory pathways suggested to be critical for 
the tumor development.5  
The integration of the HPV virus in the host genome is often located in the transcribed 
genomic region suggested as a mechanism adapted by the virus to improve the expression of some 
viral products, notably E6 and E7 viral oncogenes.6, 7 In addition, the integration of HPV type 16 was 
strongly associated with progression of precancerous lesions, i.e. cervical intraepithelial neoplasia 
grade 1 to 3 (CIN1-CIN3).8 
Genomic instability and other DNA alterations including epigenetic ones, causing changed 
gene expression, are common features in many cancers.9 Regions differentially methylated in cancers 
often co-localize with tissue-specific DNA methylated regions (T-DMR).10,11 In cervical cancer, the 
DNA methylation can occur on the integrated viral DNA but also induce aberrant DNA methylation in 
the host cell genome.12 Increased methylation of HPV type 16 has been correlated with a more 
severe cancer progression.13 Aberrant methylation status of several host genes related to cell cycle, 
apoptosis, development, cell adhesion and cellular signalling have been analyzed in clinical studies by 
Szalmaz et al. and Wentzen et al.14, 15 These meta-studies also showed that there is a large variation 
of the DNA methylation frequency, implying that new biomarkers are needed for early detection and 
progression of cervical cancer.  
In this study, we employed the Illumina Infinium Human Methylation 450 K BeadChip array 
to identify novel biomarker genes that are differentially methylated in cervical squamous cell 
carcinoma (SCC) DNA samples compared to DNA from normal cervical scrapes and CIN3 cervical 
tissue. This approach enabled us to acquire a comprehensive epigenetic signature between the 
different cervical tissues in terms of global methylation, regional methylation in CpG islands (CGI), 
shores, gene related regions (TSS, 5’UTR, gene-body, 3’UTR), and also methylation of distinct CpG 
sites that discriminates between these tissues. 
 
Results 
DNA methylation profile in cervical cancer or CIN3 compared to the normal cervical tissue 
The probe call rate was > 99% for all of the samples and 454, 215 CpG sites out of 485,577 
were included in the analysis. The PCA analysis showed that all samples were close to each other. 
The majority of the cancer samples tended to hold together, followed by the cluster of CIN3 samples 
and other cluster of the normal cervical samples (Supplementary Figure 1). The frequency 
  4 (19) 
distribution of the ∆β-values showed that cervical cancer tissue, compared to CIN3 and normal 
cervical tissue harbored hypermethylation at specific regions (data not shown). The frequency 
distribution of differentially methylated CpG sites across chromosomes showed that cancer tissue 
compared to the CIN3 and normal tissues had most differentially methylated CpG sites on 
chromosomes 1, 6 and 19 (Supplementary Figure 2). 
The unsupervised hierarchical clustering analysis distinguished normal cervical tissues from 
tissues with CIN3 lesions and cancer tissues (Figure 1). In this heatmap, sixteen of the 25 statistically 
significant CpG sites belong to an annotated gene. The first ten CpG sites, located in different genes, 
are mostly hypomethylated in the cancer tissues as well as in the tissues with CIN3 lesions compared 
to the normal tissues (Figure 1). In contrast, the remaining 15 CpG sites in specific genes are mostly 
hypermethylated both in cancer and tissues with CIN3 lesion compared to the normal tissues. The 
mean β-values for all the 25 CpG sites are shown in Table 1. 
 
Differentially methylated CpG loci and gene regions 
We analyzed the location of the hypo- and hypermethylated CpG loci in relation to the CpG 
islands and gene context. Most of the differential methylation occurred in the context of a gene 
when comparing cancer tissue to precancerous and normal tissue (Figure 2). A large fraction of the 
hypermethylated CpG loci were located in the CGI in contrast to the hypomethylated ones that were 
mostly located in the CGI shore or further away (Figure 2).  
In Supplementary Table 1 an overview of the number of differentially methylated regions 
and the range of the differences are shown comparing the three diagnostic groups. Most of the 
differentially methylated regions are found when comparing cancer tissue and normal cervical tissue. 
The majority of the events occur in the traditional gene promoter region (TSS1500, TSS200, 5’UTR, 
and 1st exon) and in the CpG islands. The comparison between cancer tissue and CIN3 tissues follow 
the same pattern. There are no differentially methylated regions reaching the criterion of ∆β of 
≥│0.2│ when comparing the CIN3 tissues and normal cervical tissues.  
Analysis of the differentially methylated regions in the vicinity of the traditional promoter 
region (TSS1500, TSS200, 5’UTR and 1st exon) in cancer tissues compared to the normal tissues 
showed that many of the hypomethylated genes in cancer were found to be involved in the immune 
system response (Table 2). The hypermethylated genes are mostly receptors and transcription 
factors involved in cell development (Table 3).  
 
Identification of functionally-related gene groups 
A total number of 74 gene ontology term clusters were generated when analyzing the 
hypomethylated CpG sites in cancer compared to normal cervical tissues. The GO_BP cluster with the 
highest enrichment score of 6.42 was related to the immune system (Supplementary Table 2). The 
GO_FAT terms included several KEGG pathways involving the immune system, such as antigen 
processing and presentation, autoimmune thyroid disease and asthma.  
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The gene ontology analysis of the hypermethylated CpG sites created three clusters, and 
GO_BP had the highest enrichment score of 36.52 (Supplementary Table 3). These gene ontology 
terms belong to the categories of cell development and cell differentiation. The GO_FAT and KEGG 
classification included categories of transcriptional regulation and DNA binding with the highest 
enrichment score of 24.41.  
 
Candidate biomarker genes 
The selection of candidate biomarker genes was based on both differentially methylated 
CpG sites generated with unsupervised hierarchical clustering and differentially methylated gene 
regions.  
From the list of genes generated with unsupervised hierarchical clustering (Table 1) the 
selection criteria were 1) Δβ-value > 0.2 between the cancer and normal tissues, and 2) a mean 
baseline (normal tissue) β-value < 0.2 of a CpG site hypomethylated in cancer or a baseline (normal 
tissue) β-value > 0.4 for a CpG site hypermethylated in cancer. This approach led to the selection of 
six genes, the best candidate biomarkers: RGS7, LHX8, STGALNAC5, TBX20, KCNA3, and ZSCAN18 
(Table 1 and Table 4), all with ≥ 9 significant CpG sites.  
From Table 2 and Table 3, displaying differentially methylated gene regions, we selected 
genes that were differentially methylated with a Δβ-value >│0.4│. The gene regions were then sorted 
according to the adjusted p-value and the top 20 regions were selected as candidates corresponding 
to 18 genes: ACAN, AJAP1, BARHL2, BOLL, C1orf114, FBXL7, GALR1, GYPC, KIF19, MIR663, PTGDR, 
S1PR4, SORCS1, TRIM58, TTYH1, VSTM2B, ZIK1, and ZNF582. The enlarged list of candidate biomarker 
genes is presented in Table 5. With exception of S1PR4, the candidate genes were hypermethylated 
in cancer compared to CIN3 and normal cervical tissues. As illustrative examples, the mean 
methylated fractions of all interrogated CpG sites in three selected genes, S1PR4, TBX20, and ZNF582 
are shown in Supplementary Figure 3. There is a stepwise increment in methylation (β-value) when 
comparing normal tissue, CIN3 tissues, and cervical cancer. We further validated the differential 
methylation of four selected genes, TBX20, RGS7, KCNA3, and S1PR4, with the Pyrosequencing assay 
technology. Supplementary Figure 4 shows the percentage methylation of the analyzed CpG sites in 
cervical cancer and normal tissues. The results are in very good agreement with our array data. The 
mean methylation of the cervical cancer tissues was higher compared to the normal cervical tissues 
in the TBX20, RGS7, and KCNA3 genes, while the S1PR4 gene was hypomethylated in cervical cancer 
tissues. We found a higher variation in the methylated fraction within the cervical cancer group 
compared to the normal cervical tissues, as detected also by the array technique (Table 1).  
 
External validation  
External validation of our candidate biomarker genes was done using the mRNA expression 
dataset from Peyon et al.16, Scotto et al.17, and Zhai et al.18 which fulfilled quality criteria of tissue 
samples and employed high quality whole-genome expression arrays. Peyon et al.16 reported probe 
sets for 21 of our 24 genes of interest whereas the two other sets reported for 14 of the genes. There 
was a good agreement with our DNA methylation data and the gene expression array; the fold 
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changes ranged between -1.09 and -2.20 for all the hypermethylated genes, see Table 4. The 
hypomethylated S1PR4 gene was as expected up-regulated in cervical cancer in one gene expression 
dataset but it was down-regulated in the two others.  
 
Discussion 
The aim of this study was to acquire a comprehensive epigenetic signature of cervical 
cancer, and to identify new potential biomarker genes that are differentially methylated in cervical 
SCC compared to CIN3 or the normal cervical tissue. Our results showed that different cellular 
pathways are hypo- and hypermethylated in cancer tissue. A short list of 24 novel candidate 
biomarker genes emerged, which was consistent with the external validation sets and could 
ultimately be clinically applicable. 
Fifteen of the 24 potential biomarker genes (ACAN, Clorf114, FBXL7, GYPC, KCNA3, KIF19, 
LHX8, MIR663, RGS7, S1PR4, SORCS1, TBX20, TRIM58, TTYH1, and VSTM2B) have not yet been 
correlated to any cancer type, while eight (AJAP1, BARHL2, BOLL, GALR1, PTGDR, ST6GALNAC5, ZIK1, 
and ZSCAN18) have been implicated in cancers other than cervical cancer (Table 4). Nevertheless, all 
of these genes are included in crucial cellular functions, such as cell signaling, gene transcription, 
immunity, glycosylation, membrane activity and ubiquitination. Therefore, the hypermethylation of 
genes involved in such processes may contribute to the accumulation of damages that can progress 
to cervical cancer. By external validation using three independent datasets, the gene expression of 
twenty three potential biomarkers was found to be down-regulated. This correlated with their 
hypermethylated state, confirming a link between DNA methylation and mRNA expression. 
In cervical carcinogenesis, both global DNA hypomethylation and hypermethylation of 
specific genes promoters has been suggested to occur.19, 20 We found here that most of the analyzed 
CpG loci were equally methylated (94%) in cervical cancer cells and normal cervical cells 
(Supplementary Table 4). However, the genome-wide DNA methylation array confirmed that 
hypermethylation in cervical cancer really occurs at specific genes (24,199 CpG sites; Supplementary 
Table 4). Even though we included more CIN3 cases precisely to increase the power to detect 
differences between CIN3 and normal tissues, the differences between the methylome of cervical 
cancer vs. normal tissues was greatest in all analyses (p- and β-values) compared to the methylome 
of CIN3 vs. normal tissues, therefore our report focuses on these differences.  
Distinctly different cellular pathways appear to be hypo- and hypermethylated. In cervical 
cancer, the hypomethylated genes were related to the immune system response (Supplementary 
Table 2); whereas the hypermethylated genes were involved in the biological processes of cell 
development, cell differentiation, and transcriptional regulation (Supplementary Table 3). Shen et 
al.21 interrogated a smaller number of CpG sites (Infinium Human Methylation 27 BeadChip) in colon, 
kidney, stomach, lung and breast cancers as well as the corresponding normal tissue; they reported 
results consistent with our methylation data performed on cervical cancer.21  
Aberrant DNA methylation signatures in cervical cancer tissue, compared to the normal 
cervical tissue, are located in different regions depending on the methylation status. 
Hypermethylated CpG sites are predominantly located in the CGIs and hypomethylated CpG sites in 
the CGI shores (Figure 2). In the gene context, most of the changes occurred in the TSS200 region 
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(Supplementary Table 1). Aberrant DNA methylation has been mostly studied in promoters with a 
CpG island. A few years back, CpG island shores were identified as potentially important regions 
harboring DNA methylation changes in colorectal cancer.11 CpG island shore methylation was 
statistically significantly correlated with clinical characteristics in breast cancer when we analyzed the 
SLC25A43 gene.22 Feber et al.23 analyzed pooled DNA from benign and malignant nerve sheath 
tumors with methylated DNA immunoprecipitation and next generation sequencing (MeDIP-seq), 
and suggested that both hypo- and hypermethylated differentially methylated regions were located 
in the CGI shore regions.23 The MeDIP-seq methodology yields a semi-quantitative methylation 
percentage and differs from the Illumina Infinium Human Methylation 450 K BeadChip that detects 
selected CpG sites at a single-nucleotide resolution in virtually all genes.24, 25  
Furthermore, methylation changes that are tumor driving were suggested to be present in 
premalignant lesions and to occur early in the field of carcinogenesis.26 From a clinical perspective, 
methylation biomarkers for cervical cancer detection and prognosis are highly needed.15 Lendvai et 
al.19 recently used MeDIP-seq to perform a genome-wide analysis of high-grade CIN3 lesions 
compared with normal cervical epithelium, and identified 80 differentially methylated regions. They 
suggested COL25A1 and KATNAL2 genes as potential biomarkers for early detection of high-grade 
cervical intraepithelial neoplasia.19 Our study also identified these two genes as differentially 
methylated in cervical cancer tissue compared to CIN3 or normal cervical tissue, but not when 
comparing CIN3 tissues and the normal cervical tissues (data not shown), indicating that these two 
genes might be late biomarkers, however they did not qualify as biomarkers according to our 
selection criteria. Our data extends the study of Lendivai et al.19 by comparing the methylome of 
cervical cancer tissues compared to the CIN3 lesions and the normal tissues. By this approach we 
generated a list of 24 novel potential biomarker genes (Table 4).  
One of our candidate biomarker gene, ZNF582, was previously shown to be 
hypermethylated in cervical cancer suggesting silencing of the ZNF582 gene in cervical neoplasms,27( 
Suplementary Figure 3). Although the biological function of ZNF582 is not yet well characterized, it 
could be a tumor suppressor gene as well as potential candidate gene for molecular cervical cancer 
screening.27 Another highly interesting gene is GALR1, which inhibits a key regulatory enzyme 
adenylyl cyclase. This gene was suggested to be hypermethylated in a subset of head and neck 
cancer caused by oncogenic HPV types, notably HPV 16.28 Thus, frequent promoter hypermethylation 
of GALR1 and cellular growth suppression after re-expression of the gene supports the hypothesis 
that GALR1 could be a tumor suppressor gene in head and neck cancer,28 as well as in cervical cancer 
(our study). 
Our findings of hypomethylated genes in the immune system provide strong evidence that 
the immune response is under control of hypermethylation in normal cells, while in cancer cells, 
these genes become active by losing the methylation mark in the gene promoter region which 
represses the gene expression. One example is the hypomethylated AIM2 gene, whose functional 
protein forms an inflammasome, resulting in caspase activation in inflammatory cells. This induction 
of inflammatory cell response could occur in cervical cancer cells due to the hypomethylation of 
genes such as the AIM2 gene. Furthermore, AIM2 protein has been found overexpressed in a wide 
variety of tumor types, including neuroectodermal tumors,29 pancreatic cancer,30 and in leukemias.31 
Another interesting hypomethylated gene is HLA-DPB1, whose gene product belongs to the 
HLA class II molecules, which plays a central role in the immune system by presenting peptides 
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derived from extracellular proteins. There is evidence that HLA-DP participates in the functional T-cell 
responses against HPV in cervical cancer.32 The host immune response to HPV is generally at low-
level because HPV is shielded in the basal epithelial cells from the circulating immune cells during 
initial stages of the infection. Furthermore, HPV employs several mechanisms to down-regulate 
innate and cell-mediated immunity.33 This is confined to the early stages of infection since it is known 
that functionally active immune responses are generated at later stages of the HPV infection.34 Thus, 
our findings in cervical cancer are consistent with an immune response against HPV, which is 
activated through hypomethylation of specific genes included in the immune response and 
inflammatory reactions. 
The immune system, upon activation by hypomethylation, can prevent tumor development 
by suppressing the viral infection, prevent an inflammatory environment leading to tumorgenesis, 
and identify tumor cells based on their antigen expression and eliminate them.35 Inflammatory cells 
are suggested to affect the tumor microenvironment, which in turn can promote or repress the 
tumor growth.36 The theoretical model of aberrant DNA methylation induced by chronic 
inflammation involves cytokine production TNFα, IL-1β, and oxidative stress in epithelial cells.36, 37 
Thus, without adequate immune responses the transformation to cancer might be quicker. This is the 
case of the adenovirus 12, which has the capability to turn off the immune system genes which may 
lead to tumor progression.38 Tumor tissue may contain increased amounts of leukocytes of various 
types, which could partly account for the observed hypomethylation of immune-system-related 
genes. The recent introduction into clinical practice of liquid-based cervical cytology may offer 
opportunities to address this issue in future studies.  
In order to determine if DNA methylation changes occur early or late in cervical 
carcinogenesis the genome-wide DNA methylation studies should extend to lower CIN grades, CIN1 
and CIN2 as well as atypical squamous cells of undetermined significance (ASCUS). However, our 
study clearly indicates that DNA methylation profile of specific genes in samples with high-grade 
cervical lesions (CIN3) is located between samples with normal diagnosis and samples with invasive 
cervical cancer (Supplementary Figure 1), but closer to cluster of normal samples, as exemplified by 
specific CpG sites in the ZNF582, TBX20 and S1PR4 genes (Supplementary Figure 3).  
We have validated our array results with an independent method analyzing the methylated 
fraction of four genes (Supplementary Figure 4). Our results suggest as previously reported by Cachill 
et al.39 and Deneberg et al.40, that the Illumina Human DNA methylation 450K array measures 
differential DNA methylation comparable to the golden standard Pyrosequencing assay technology.  
   
Conclusion 
In this study, we selected candidate genes with CpG sites highly methylated in cervical 
cancer tissue and without methylation in normal cervical tissue. This combination provides an 
optimal condition for a successful diagnostic test. The results highlight the extensive differential 
methylation signature in HPV induced cervical cancer tissue compared to CIN3 or normal cervical 
tissues. The 24 candidate biomarkers that we identified represent several types of mechanisms in the 
cellular machinery that are epigenetically deregulated, such as membrane receptor function, 
intracellular signaling, and gene transcription. External validation confirmed a link between DNA 
methylation and mRNA levels for these genes. Considering the extensive hypomethylation of genes 
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involved in the immune system, epigenetic therapy and immune therapy might need to be combined 
when treating cervical cancer. Understanding of the functional role of DNA methylation alterations in 
cancer genomes may prove to be clinically applicable in disease diagnostics and prognostics, and may 
guide the development of new epigenetic therapies. 
 
Materials and methods 
Study group 
The cervical specimens were collected in the Sisters of Mercy Hospital, Zagreb, Croatia 
during the period from 2004 to 2011. The clinical characteristics of the specimens are presented in 
Supplementary Table 5. The cytological diagnoses were obtained for normal cervical smears, high-
grade squamous intraepithelial lesion (HSIL)/CIN3, while cervical SCC samples were defined by 
histopathology.41 Subsequently, cervical specimens were tested and typed for HPV.42 
The cervical sample collection is regulated through Laboratory service request forms that 
have to be signed and approved by the practicing physician. The extracted DNA from cervical 
specimens was processed without initial knowledge of patient data (age, diagnosis, HPV detection 
and typing result). The study was approved by the Ethical Board of the Rudjer Boskovic Institute, as 
well as the Ethical Board of Sisters of Mercy Hospital, and conforms to the Helsinki declaration 
(DoH/Oct2008). The Ethical Review Board, Uppsala, approved the Swedish participation in this study.  
 
DNA preparation 
DNA from cervical cell samples was isolated on the BioRobot EZ1 (Qiagen, Hilden, Germany) 
according to the manufacturer’s instruction. After DNA extraction, the purified DNA was dissolved in 
50–100 μl of tri-distillate sterile water and stored at –20°C until further analysis. Each DNA was 
analyzed by electrophoresis on 1% agarose gels and spectrophotometrically.43 
 
HPV detection and typing 
Three sets of consensus primers for HPV detection were used: PGMY09/PGMY11,44 
L1C1/L1C2-1/L1C2-2 45 and GP5+/GP6+.46 The quality of the isolated DNA was tested by amplification 
of the 268 bp sequence of the β-globin gene using PC04/GH20 primers47 in a multiplex PCR with 
PGMY primers. Type-specific primers for HPV types 6/11, 16, 18, 31, 33, 45, 52 and 58 were used for 
HPV typing according to Milutin-Gasperov et al., 2007.42 Aliquots of each PCR product (10 μl) were 
analyzed by electrophoresis on 2% agarose gels stained with ethidium bromide. The amplified 
products were visualized by UV irradiation of the gels either by ImageMaster VDS (Pharmacia 
Biotech) or UVItec Cambridge (Alliance 4.7). 
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Methylation array 
The Illumina Infinium Human Methylation 450 K BeadChip (Illumina, Sweden) includes 
485,577 CpG sites located all over the genome.24 The quality and integrity of the samples were 
evaluated with Nano Drop and gel electrophoresis; samples were included if the ratio A260/280 was 
between 1.7-1.9, the ratio A 260/230 was > 1 and the samples resolved on gel electrophoresis showed a 
distinct DNA band > 10,000 bp. In this study 20 normal cervical samples (HPV negative), 18 samples 
with CIN3 lesions (HPV positive) and 6 cervical cancer tissues (HPV positive) were included. The DNA 
methylation assay was performed as follows. Briefly, approximately 500 ng of DNA from cancer, CIN3 
lesions, and normal cervical tissues were bisulfite treated with Zymo EZ DNA Methylation Gold kit 
(Zymo Research, USA) according to manufacturer’s procedure. After the bisulfite treatment, 200 ng 
DNA was subjected to the whole genome amplification (WGA) and enzymatic digestion with reagents 
provided within the Infinium Human Methylation 450K kit (Illumina, Sweden). The hybridization of 
the samples on the BeadChips and washing procedures followed the standard procedures obtained 
from Illumina. The iScan scanner (Illumina, Sweden) was used to read the BeadChips and the data 
collection was performed in the GenomeStudio software (version 1.0).  
 
Data processing 
The Infinium Human 450K Methylation Bead chip has several built in sample dependent and 
independent controls that measure the processing of the chip. They were analyzed in the Genome 
Studio software with the Dash-Board module, prior to further statistical analyzes. The probe call rate 
for a passed sample should be > 98%, and the detection p-value for the probes should be < 0.01, 
otherwise they were excluded. The β-value generated for each CpG locus measures the intensity of 
methylated (β = 1) and un-methylated probes (β = 0). It is calculated as β = [M/(M+U+100)], where M 
= methylated allele and U = un-methylated allele. The study cohort contains only women; therefore 
the Y-chromosome was excluded from the analysis. The raw -values were generated with the 
GenomeBead studio using the settings normalisation controls and background subtraction. This data 
has been deposited to the Gene Expression Omnibus database under the accession number 
GSE46306. 
A CpG locus was considered differentially methylated if the -value was ≥0.2 and the 
adjusted p-value < 0.05. This cut-off value of 0.2 represents the 99% confidence interval of the 
detection limit.25 
  
Unsupervised clustering of CpG loci and DAVID analysis 
Heat map showing clustering of the patient samples was performed based on p-value < 
0.05 and ∆-value ± 0.5 between CIN3 tissues and normal tissues. They were produced with the 
Illumina Methylation Analyzer (IMA) package version 2.1.1 (Illumina, Sweden). The Database for 
Annotation, Visualization and Integrated Discovery (DAVID) 48 was used to analyse biological features 
associated with genes hypo- or hypermethylated in cervical cancer compared with normal cervical 
tissue. The gene lists were obtained with the criteria p-value < 0.05 and a more stringent -value of 
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> │0.3│ (between cancer and normal tissues) due to the input limit of genes to the DAVID tool. The 
gene ontology (GO) groups were clustered into functional annotation referring to biological process 
(GO_BP), cellular component (GO_CC) and molecular function (GO_MF). GO_FAT terms were also 
retrieved to filter the broadest GO categories. In addition, the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) database was used to identify functional gene groups and ontology terms that are 
significantly overrepresented.  
 
Differentially methylated CpG loci and gene regions 
The CpG loci were categorised as either hypermethylated (positive -value) or 
hypomethylated (negative -value). The CpG loci were then categorized in the context of (I) CpG 
islands, CpG shores, CpG shelves or others and (II) genomic location of TSS1500 (1.5 kb within 
transcriptional start site), TSS200 (200 bp within transcriptional start site), 5’UTR (5' untranslated 
region) and 1st exon, gene body and 3’UTR (3' untranslated region) or others. To compare the regions 
(CpG island, CpG shore, CpG shelves, TSS1500, TSS200, 5’UTR, 1st exon, gene body and 3’UTR) 
between the different diagnostic groups, the median -value was calculated including all the CpG 
sites in the analysed region. Each region contains on average 1.53 – 9.92 probes.25 
 
External validation of the candidate biomarker genes 
Three datasets GSE6791,16 GSE9750,17 and GSE780318 deposited to the Gene Expression 
Omnibus (GEO) database were used for external validation of mRNA expression of candidate 
biomarker genes. The datasets measured gene expression by the Affymetrix GeneChip Human 
genome U133 Plus 2.0 (GSE6791) array and Affymetrix HG-U133A array (GSE9750 and GSE7803). The 
GES6791dataset was composed of 20 cervical cancer samples (17 HPV+, 3 HPV-) and 8 normal 
cervical samples (HPV-); the GSE9750 dataset of 27 cervical cancers (HPV+) and 24 normal cervical 
tissues (HPV-); and GSE7803 dataset of 24 cervical cancer tissues (HPV+) and 10 normal cervical 
tissues (HPV-). Using the online tool GEO2R (www.ncbi.nlm.nih.-gov/geo/geo2r), the log fold change 
(FC) was calculated to estimate the differences in the gene expression in cervical cancer compared to 
the normal cervical samples. The unadjusted p-values < 0.05 were considered as statistically 
significant, since these analyses were hypothesis driven. 
 
Pyrosequencing validation of differential methylation 
We developed assays for the following genes: TBX20, RGS7, KCNA3, and S1PR4. The PCR 
and sequencing primers were designed to assess the exactly same CpG sites analyzed by the array. 
All primers were purchased from www.biomers.net (Ulm/Donau, Germany). In the Supplementary 
Table 6, the sequences, amplicon sizes, and the optimal annealing temperatures are indicated.  
The analysis was performed on 5 cervical normal and 5 cancer tissues, which were already 
tested by Illumina Infinium Human Methylation 450 K BeadChip array. Briefly, approximately 500 ng 
extracted DNA was used for the bisulfite treatment performed with the EZ DNA Methylation Gold kit 
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according to the instructions by the manufacturer and eluted in 20 µl elution buffer (Zymo Research, 
Orion Diagnostica, Sweden). The PCR reactions were performed in a total volume of 40 µl with the 
KAPPA2G Robust HotStarTaq DNA Polymerase Kit (Kapa Biosystems, Inc.), containing 0.10 µmol/L of 
each primer, 0.5 units of Taq polymerase, 1.5 mM MgCl2, and 0.1 mM each of dGTP, dATP, dTTP, 
dCTP and 50 ng of bisulphite treated DNA was added as template. The PCR reaction for the RGS7 
gene contained also the 1X Enhancer solution provided in the kit. The PCR program was as follows: 
initial denaturation step of 1 min at 95oC, followed by 45 cycles of 30 sec denaturation at 95oC, 
specific annealing Ta for 30 sec and extension for 30 sec at 72oC and one cycle of final extension for 
30 sec at 72oC. Sequencing was performed using a Pyromark Gold Q96 Reagent Kit and a PSQ 96ID 
system (Qiagen) as described previously by Farkas et al.49 The nucleotide addition order was 
optimized by the Pyro Q-CpG software version 1.0.9 (Qiagen) and the results were automatically 
analyzed using the same software. 
 
Statistical analysis 
All statistical analyses were performed using the R software with the IMA package.50 The 
raw β-values were arcsine square root transformed and the empirical Bayes moderated t-statistic 
was used to generate the p-values.51 The Benjamini-Hochberg method was used to adjust the p-
values for multiple testing.52 For site-level analysis the mean -values were used and for the 
regional analysis median -values value was calculated including all CpG sites in one region. The 
principal component analysis (PCA) was performed to visualise the difference in DNA methylation 
between the cancer and normal tissue samples. In the DAVID analysis the statistic used was the 
modified Fishers exact p-value, adjusted for multiple testing with the Bonferroni method.53  
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Legends to Figures 
 
Figure 1. Unsupervised clustering analysis of the normal cervical tissue (N), CIN3 tissue (CIN3), and 
the cervical cancer tissue (CC).  
The color gradient green to red displays the β-value and can range from 0 – 1. 
 
Figure 2. Distribution of hypermethylated and hypomethylated CpG locus in CpG island (CGI), CpG 
island shore, CpG island shelves and other region. 
 
Legends to Supplementary Figures 
 
Supplementary Figure 1. Principal component analysis.  
The grouping of cancer (green), precancerous (CIN3, blue) and normal cervical samples (red). 
 
Supplementary Figure 2. Frequency distribution of hypo- and hypermethylated loci on different 
chromosomes.  
The X chromosome is denoted as 23. 
 
 
Supplementary Figure 3. Interrogated CpG sites in the ZNF582, S1PR4, and TBX20 genes. 
 
Supplementary Figure 4. Validation of the differential methylation with the Pyrosequencing assay 
technology of the TBX20, RGS7, KCNA3, and S1PR4 genes in cervical cancer tissue (CC) and normal 
cervical tissue (NT). The horizontal line is displaying the mean methylated fraction of the group. 
 
 
